| 6 |
Achondroplasia, creeper |
1 |
Target evidence
|
56.5 |
| 8 |
Acromegaly |
2 |
Target evidence
|
55.3 |
| 17 |
Adrenal insufficiency, congenital, CYP11A1-related |
2 |
Drug
|
64.6 |
| 31 |
Coat colour, dilution, MLPH-related |
7 |
Target evidence
|
58.2 |
| 42 |
Analphalipoproteinaemia, ABCA1-related |
2 |
Drug
|
65.9 |
| 59 |
Arachnomelia, SUOX-related |
1 |
Target evidence
|
58.1 |
| 78 |
Ataxia, cerebellar, neonatal, GRM1-related |
1 |
Target evidence
|
60.9 |
| 151 |
Brachyspina |
1 |
Target evidence
|
58.0 |
| 155 |
C3 deficiency |
3 |
Drug
|
69.5 |
| 156 |
C8 deficiency |
1 |
Human gene
|
34.0 |
| 162 |
Cardiomyopathy, dilated |
11 |
Drug
|
53.6 |
| 175 |
Cerebellar abiotrophy |
9 |
Human gene
|
35.0 |
| 185 |
Chediak-Higashi syndrome |
5 |
Target evidence
|
74.9 |
| 194 |
Citrullinaemia |
2 |
Target evidence
|
76.9 |
| 202 |
Coat/skin colour, oculocutaneous albinism type I (OCA1), TYR-related |
33 |
Drug
|
67.4 |
| 209 |
Coat colour, dominant white |
13 |
Drug
|
63.1 |
| 214 |
Coat colour, white spotting |
7 |
Target evidence
|
57.1 |
| 220 |
Severe combined immunodeficiency disease, autosomal, PRKDC-related |
2 |
Drug
|
60.8 |
| 248 |
Neutropenia, cyclic |
1 |
Target evidence
|
58.3 |
| 256 |
Cystinuria, type I - A |
2 |
Target evidence
|
86.6 |
| 262 |
Deficiency of uridine monophosphate synthase |
2 |
Drug
|
81.1 |
| 263 |
Degenerative myelopathy |
1 |
Human gene
|
29.0 |
| 284 |
Diabetes mellitus, type 2 |
7 |
Drug
|
89.4 |
| 309 |
Dwarfism, sex-linked |
1 |
Drug
|
83.1 |
| 317 |
Ears, crop |
1 |
Target evidence
|
55.7 |
| 319 |
Ears, folded (drop vs prick) |
4 |
Drug
|
60.7 |
| 323 |
Ectodermal dysplasia |
2 |
Target evidence
|
48.6 |
| 328 |
Dermatosparaxis Ehlers-Danlos syndrome (dEDS), ADAMTS2-related |
4 |
Target evidence
|
66.0 |
| 341 |
Epidermolysis bullosa, dystrophic |
5 |
Drug
|
85.2 |
| 344 |
Epilepsy |
12 |
Drug
|
67.5 |
| 361 |
Factor VII deficiency |
2 |
Drug
|
84.2 |
| 363 |
Factor XI deficiency |
3 |
Drug
|
69.4 |
| 364 |
Factor XII deficiency |
4 |
Drug
|
71.1 |
| 366 |
Fanconi syndrome |
4 |
Target evidence
|
63.7 |
| 369 |
Feather colour, oculocutaneous albinism type I (OCA1), TYR-related |
6 |
Drug
|
61.4 |
| 370 |
Feather colour, SLC45A2-related |
6 |
Target evidence
|
66.6 |
| 388 |
Fibrodysplasia ossificans |
3 |
Drug
|
85.6 |
| 394 |
Frizzle, KRT6A-related |
1 |
Human gene
|
21.0 |
| 396 |
Fucosidosis, alpha |
2 |
Target evidence
|
61.2 |
| 402 |
Gangliosidosis, GM1 |
5 |
Target evidence
|
64.7 |
| 418 |
Glycogen storage disease Ia |
1 |
Target evidence
|
82.9 |
| 419 |
Glycogen storage disease II |
6 |
Drug
|
61.3 |
| 420 |
Glycogen storage disease IV |
3 |
Target evidence
|
69.7 |
| 421 |
Glycogen storage disease VII |
1 |
Target evidence
|
77.6 |
| 424 |
Goitre, familial |
11 |
Human gene
|
40.0 |
| 437 |
Haemophilia A |
7 |
Drug
|
96.7 |
| 438 |
Haemophilia B |
4 |
Drug
|
96.0 |
| 452 |
Henny feathering |
1 |
Drug
|
53.6 |
| 483 |
Polled/Horns |
8 |
Human gene
|
29.0 |
| 487 |
Hydrocephalus |
12 |
Target evidence
|
63.9 |